- Medicine Name: Fycompa
- Generic Name: Perampanel
- Dosage Form: Tablets and Oral Suspension
- Strength: 2 mg/4 mg/6 mg/8 mg/10 mg/12 mg, and 0.5 mg/mL
- Manufactured By: Eisai Inc.
Fycompa contains active pharmaceutical ingredient Perampanel. It is a non-competitive AMPA glutamate receptor antagonist used as adjunctive therapy to treat Partial-Onset Seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older, and Primary Generalized Tonic-Clonic (PGTC) Seizures in patients with epilepsy aged 12 years and older
Dosage for Partial-Onset Seizures: The recommended starting dosage is 2 mg once a day taken orally at bedtime. The dosage of Fycompa tablets can be increased by increments of 2 mg once a day no more often than at weekly intervals. The maintenance dose range is 8 to 12 mg once daily in the absence of enzyme-inducing antiepileptic drugs, although some individuals may respond with 4 mg daily dose. A dose of 12 mg once a day resulted in somewhat higher reductions in the rates of seizure than 8 mg once daily dose but with a substantial increase in side effects. Adjust individual dosing on behalf of clinical response as well as tolerability.
Dosage for Primary Generalized Tonic-Clonic Seizures: The recommended starting dosage is 2 mg once a day taken orally at bedtime. The dosage of Fycompa can be increased by increments of 2 mg once daily no more often than at weekly intervals. In individuals not using enzyme-inducing antiepileptic drugs, the maintenance dose is 8 mg once daily taken at bedtime. Those who are tolerating Fycompa 8 mg once a day and need further reduction of seizures may consider a dose increase up to 12 mg once daily in case tolerated. Adjust individual dosing on behalf of clinical response as well as tolerability.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.